Literature DB >> 3314617

Growth inhibition of Cryptococcus neoformans by human alveolar macrophages.

P B Weinberg1, S Becker, D L Granger, H S Koren.   

Abstract

Macrophage cytotoxicity for Cryptococcus neoformans was investigated by culturing human alveolar macrophage (AM) with a thin-capsuled clone of C. neoformans in a polypropylene culture tube assay system. Yeast replication was quantitated by electronic particle counting after detergent lysis of AM and viability by quantitative plate counts. Under appropriate conditions, fungal replication was inhibited in the presence of human AM. This effect persisted over the 48-h time course that was evaluated. During this period, organisms in medium alone proliferated rapidly, doubling their number every 4 h. Human AM did not require endotoxin, fetal calf serum, or specific rabbit anticryptococcal antibody for fungistasis. Under these conditions, microscopic evaluation of a cytocentrifuge preparation of AM-yeast cocultures, stained by a modified Giemsa technique, revealed all the fungi to be extracellular. In the presence of 10% fresh human serum, AM phagocytized C. neoformans and exhibited fungicidal activity. Tumor necrosis factor did not affect the replication rate of the yeast. These findings suggest that there may be at least 2 mechanisms by which human AM protect against C. neoformans. One is serum-independent and extracellular and results in fungistasis, and the other is dependent on a serum factor and leads to intracellular inhibition of growth and possibly killing of the organism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3314617     DOI: 10.1164/ajrccm/136.5.1242

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  20 in total

Review 1.  Role of phagocytosis in the virulence of Cryptococcus neoformans.

Authors:  Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2004-10

2.  Human natural killer cells do not inhibit growth of Cryptococcus neoformans in the absence of antibody.

Authors:  M F Miller; T G Mitchell; W J Storkus; J R Dawson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

3.  The cryptococcal enzyme inositol phosphosphingolipid-phospholipase C confers resistance to the antifungal effects of macrophages and promotes fungal dissemination to the central nervous system.

Authors:  John M Shea; Talar B Kechichian; Chiara Luberto; Maurizio Del Poeta
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

4.  Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection.

Authors:  M Feldmesser; Y Kress; P Novikoff; A Casadevall
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

5.  In vivo interaction between alveolar macrophages and Cryptococcus neoformans.

Authors:  K Nessa; N T Gross; C Jarstrand; A Johansson; P Camner
Journal:  Mycopathologia       Date:  1997       Impact factor: 2.574

6.  Intravascular granuloma induced by intravenous inoculation of Cryptococcus neoformans.

Authors:  H Yamaoka; N Sakaguchi; K Sano; M Ito
Journal:  Mycopathologia       Date:  1996       Impact factor: 2.574

7.  Effect of endothelial cells on phagocyte-mediated anticryptococcal activity.

Authors:  S A Roseff; S M Levitz
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Killing of Cryptococcus neoformans strains by human neutrophils and monocytes.

Authors:  M F Miller; T G Mitchell
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

9.  Effect of in vivo macrophage colony-stimulating factor on fungistasis of bronchoalveolar and peritoneal macrophages against Cryptococcus neoformans.

Authors:  F Nassar; E Brummer; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Effect of macrophage colony-stimulating factor on anticryptococcal activity of bronchoalveolar macrophages: synergy with fluconazole for killing.

Authors:  E Brummer; F Nassar; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.